RxDoctor Payments Data

Lisa Higley, DO

Internal Medicine · Clinton Twp, MINPI 1063464618

Payments from drug & device makers

$2,732in general payments, 2019–2025

Across 44 payments — averaging $62.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$651
  • Amgen$425
  • AstraZeneca$419
  • Abbott$304
  • AbbVie$257
  • GSK$235
  • plus $441 from 8 others

What the payments were for

  • Food & beverage$2,732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,732 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$252,732
Medicare patients
294
Services billed
6,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$98,014
OzempicSemaglutide64$77,362
EliquisApixaban40$44,789
FarxigaDapagliflozin Propanediol30$38,813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,020
JanuviaSitagliptin Phosphate26$29,515
XareltoRivaroxaban13$20,588
Breo ElliptaFluticasone/Vilanterol15$12,540
Tiotropium Bromide13$7,496
Atorvastatin Calcium493$6,213
Levothyroxine Sodium473$6,069
Losartan Potassium405$5,753
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,457
Arnuity ElliptaFluticasone Furoate11$4,128
Rosuvastatin Calcium326$3,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$651$77,36264 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta$235$53,14587 claims
PfizerEliquis, Prempro$36$47,54753 claims
AstraZenecaFarxiga$419$38,81330 claims
MerckJanuvia$82$29,51526 claims
Johnson & JohnsonXarelto$92$20,58813 claims
AbbVieSynthroid$257$2,06931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Clinton Twp

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →